Cite
HARVARD Citation
Bond, M. et al. (2023). FOLFOXIRI vs FOLFOX/FOLFIRI + bevacizumab in patients with initially unresectable colorectal liver metastases and right-sided and/or RAS/BRAFV600E mutated primary tumor: phase III CAIRO5 study. European journal of surgical oncology. 49 (2), pp. e24-. [Online].